C-rel (NFkB) Antibody (C-term)
Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, E |
---|---|
Primary Accession | Q04864 |
Reactivity | Human, Mouse |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | Rabbit IgG |
Calculated MW | 68520 Da |
Antigen Region | 586-619 aa |
Gene ID | 5966 |
---|---|
Other Names | Proto-oncogene c-Rel, REL |
Target/Specificity | This C-rel (NFkB) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 586-619 amino acids from the C-terminal region of human C-rel (NFkB). |
Dilution | WB~~1:1000 |
Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
Precautions | C-rel (NFkB) Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | REL |
---|---|
Function | Proto-oncogene that may play a role in differentiation and lymphopoiesis. NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post- translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I- kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. The NF-kappa-B heterodimer RELA/p65- c-Rel is a transcriptional activator. |
Cellular Location | Nucleus. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Nuclear factor (NF)-kappa B is a sequence specific transcriptional activator that binds to the intronic enhancer of kappa light chain gene in B lymphocytes. NF-kB regulates the expression of a wide variety of genes that involved in apoptosis, viral life cycle, tumorigenesis, autoimmune diseases and inflammation. NF-kB is a heterodimer of members of the rel family of proteins such as p50, p65, and c-rel. In most cells, inhibitory IkB proteins sequester NF-kB/Rel in the cytoplasm. Cellular stimulation precipitates degradation of IkB and modification of NF-kB/Rel proteins, permitting translocation of NF-kB/Rel (c-Rel and RelA) to the nucleus for action on target genes. The important role of c-Rel in B-cell development, growth, and survival has been intensively studied, as well as its function in differentiation and lymphopoiesis (particularly lymphoid cancer).
References
Jain, A., et al., J. Clin. Invest. 114(11):1593-1602 (2004).
Xiao, Q., et al., Appl. Immunohistochem. Mol. Morphol. 12(3):211-215 (2004).
Houldsworth, J., et al., Blood 103(5):1862-1868 (2004).
Phelps, C.B., et al., Oncogene 23(6):1229-1238 (2004).
Bernard, D., et al., Cancer Res. 64(2):472-481 (2004).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.